Seoul, South Korea

Sung Jo Choi

This inventor holds 1 USPTO granted patent. Top assignee: Chong Kun Dang Corporation. Active years: 2000.


% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2000

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Sung Jo Choi

Introduction

Sung Jo Choi is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on nucleoside derivatives. His expertise and dedication to research have led to the development of valuable patents that enhance medical science.

Latest Patents

Sung Jo Choi holds a patent for "Nucleoside derivatives and process for preparing thereof." This patent represents a crucial advancement in the preparation of nucleoside compounds, which are essential in various therapeutic applications. His work in this area showcases his commitment to improving healthcare solutions.

Career Highlights

Choi is currently employed at Chong Kun Dang Corporation, a prominent pharmaceutical company in South Korea. His role at the company allows him to apply his innovative ideas and contribute to the development of new medical products. With 1 patent to his name, he has established himself as a valuable asset in the field of pharmaceutical research.

Collaborations

Throughout his career, Sung Jo Choi has collaborated with talented individuals such as Jung Woo Kim and Chong Ryul Lee. These partnerships have fostered a creative environment that encourages the exchange of ideas and enhances the quality of their research.

Conclusion

Sung Jo Choi's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his importance as an inventor. His work continues to impact the medical community positively, paving the way for future advancements.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…